10 Jun 2021 OXURION confirms Institutional Review Board approval and submission of the Investigational New Drug Application to the FDA to start Phase 2 Study evaluating THR-687 for Diabetic Macular Edema (DME) Member news
08 Jun 2021 OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) Member news
02 Jun 2021 RheaVita closes EUR 2.5 million Series A Financing co-led by Novalis Biotech Acceleration and PMV Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us